Dave: You've used the word dilution more times today than you have in the past year combined. I don't believe there was ever an expectation of upfront money from the CLIA partner. If there was, it wasn't going to be much. Instead, they signed the Master Service Agreement and kept 100% control of the asset. None of that has anything to do with upfront money from a JV partnership, which I still expect to happen. You keep saying, we got this master service agreement INSTEAD of something else and I don't know what exactly you were expecting. It's not time for the JV partnership yet, but all of this will add value to that partnership when it is time. CLIA first, Partner next ($$$), then FDA approval. That process has been clear since January/February.
Either you trust GC and the BOD or you don't. You say you do, but it doesn't appear that way today.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links